Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 32 citing articles:

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 113
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 106
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 78
The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation
Mohammad Sobhan Karvandi, Farzam Sheikhzadeh Hesari, Amir Reza Aref, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 45
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kallirhoe Kalinderi, Vasileios Papaliagkas, Liana Fidani
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3812-3812
Open Access | Times Cited: 18
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 63
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
Meiyuan Dong, Song Wen, Ligang Zhou
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 2583-2597
Open Access | Times Cited: 43
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease
Niklas Reich, Christian Hölscher
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101122-101122
Open Access | Times Cited: 14
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9583-9583
Open Access | Times Cited: 37
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 16
Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease
Xiaoyan Yang, Peng Feng, Rong Ji, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 5, pp. 445-460
Closed Access | Times Cited: 26
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
Christian Hölscher
Frontiers in Synaptic Neuroscience (2022) Vol. 14
Open Access | Times Cited: 24
Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy
Xiaoyan Yang, Peng Feng, Hongxu Zhu, et al.
View (2025)
Open Access
α-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson’s disease rat model via activating Nrf2/HO-1 and suppressing NF-κB signaling pathway
Bingxu Huang, Guiqiu Hu, Xiaofeng Zong, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109698-109698
Closed Access | Times Cited: 12
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
Giuseppe Lisco, Anna De Tullio, Michele Iovino, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2993-2993
Open Access | Times Cited: 11
Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease
Aanchal Verma, Ahsas Goyal
European Journal of Pharmacology (2024) Vol. 982, pp. 176936-176936
Closed Access | Times Cited: 4
Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
Zijuan Zhang, Hai Li, Yunfang Su, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 18
Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving
Julienne Haas, Daniela Berg, Anja Bosy‐Westphal, et al.
Nutrients (2022) Vol. 14, Iss. 15, pp. 3240-3240
Open Access | Times Cited: 16
Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 8, pp. 1671-1677
Open Access | Times Cited: 10
Antidiabetic drugs in Parkinson’s disease
Yoshajandith Aguirre-Vidal, Sergio Montes, Ana Carolina Mota-López, et al.
Clinical Parkinsonism & Related Disorders (2024) Vol. 11, pp. 100265-100265
Open Access | Times Cited: 3
A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease
Zijuan Zhang, Ming Shi, Zhengmin Li, et al.
Parkinson s Disease (2023) Vol. 2023, pp. 1-13
Open Access | Times Cited: 8
DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model
Lingyu Zhang, Chun Li, Zijuan Zhang, et al.
Parkinson s Disease (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 13
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha Neha, Zitin Wali, Pinky Pinky, et al.
Ageing Research Reviews (2023) Vol. 93, pp. 102134-102134
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top